CNTA
Centessa Pharmaceuticals plc
Key Financials
Revenue
$15.0M
↑ Infinity%
Operating Income
$-207692000
↓ 3.3%
Net Income
$-197532000
↑ 16.2%
Total Liabilities
$160.6M
↓ 8.3%
Total Assets
$687.5M
↑ 19.2%
EPS (Diluted)
$-1.46
↑ 29.1%
Shareholders' Equity
$526.9M
↑ 31.2%
Cash & Equivalents
$61.3M
↓ 84.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 6/26/2026 | View on SEC |
| SCHEDULE 13D | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
| 4 | 6/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CNTA |
| Company Name | Centessa Pharmaceuticals plc |
| CIK | 1847903 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | X0 |
| Phone | 44 7391 789784 |